MedTrace Logo

Gut Microbiome and p-Inulin in Hemodialysis

NCT02572882 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2022-10-20

Study results available
· View outcomes & findings →

Summary

The Microbiome trial is a non-randomized, open-label, sequential, multi-center study of p-inulin for patients with hemodialysis-dependent end-stage renal disease.

Conditions

  • End-Stage Renal Disease
  • Gut Microbiome Dysbiosis

Interventions

DIETARY_SUPPLEMENT

p-inulin

12 week self-administered treatment phase

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Brigham and Women's Hospital

    collaborator OTHER

  • George Washington University

    collaborator OTHER

  • Vanderbilt University

    collaborator OTHER

  • University of Washington

    collaborator OTHER

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Laura Dember, MD · University of Pennsylvania

  • J Richard Landis, PhD · Perelman School of Medicine at the University of Pennsylvania

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-01-24
Completion
2019-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02572882 on ClinicalTrials.gov